Safety, Efficacy and Distribution of Doxorubicin Loaded Radiopaque Beads in Chemoembolization in Intermediate Stage Hepatocellular Carcinoma (HCC) with Correlation with Local Response

Malagari, Katerina; Kiakidis, Th; Moschouris, Hip.; Deutsch, M.; Tanteles, Savvas; Pantou, Eir.; Panagiotou, Ir; Koskinas, John; Glantzounis, Georgios K.; Alexopoulou, Alexandra; Filippiadis, Dimitrios; Brountzos, Elias; Kelekis, Nikolaos

doi:10.1007/s00270-022-03346-1

Cited by 1 publication

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to analyze factors involved in anthracycline chemosensitivity, since for intermediate stage HCC, chemoembolization is recommended 47,48 and anthracycline has been reported to be more effective than other chemicals for chemoembolization. [49][50][51] The results obtained in the current study are supported by previous study demonstrating that BCL-xL expression is inhibited in BCL11B knockdown cells and thymocytes of BCL11B knockout mice 22 due to transcriptional repression. A different expression changes between HLE and HepG2 cell lines might be due to the characteristics of the cells, that is, invasive and poorly differentiated HLE cells and noninvasive and hepatoblastoma-oriented HepG2 cells.…”

Section: Discussionsupporting

confidence: 89%

“…The mechanisms involved activation of anti‐apoptotic proteins, including BCL‐xL. It is important to analyze factors involved in anthracycline chemosensitivity, since for intermediate stage HCC, chemoembolization is recommended 47,48 and anthracycline has been reported to be more effective than other chemicals for chemoembolization 49–51 . The results obtained in the current study are supported by previous study demonstrating that BCL‐xL expression is inhibited in BCL11B knockdown cells and thymocytes of BCL11B knockout mice 22 due to transcriptional repression.…”

Section: Discussionsupporting

confidence: 84%

See 1 more Smart Citation

BCL11B expression in hepatocellular carcinoma relates to chemosensitivity and clinical prognosis

et al. 2023

View full text Add to dashboard Cite

IntroductionB‐cell lymphoma/leukemia 11B (BCL11B) is a subunit of SWI/SNF chromatin remodeling complexes and functions in cell cycle regulation and apoptosis upon DNA replication stress and damages via transcription. Many malignancies were reported to exhibit changes in BCL11B gene expression; however, no study has focused on the relationship between BCL11B and hepatocellular carcinoma, which potentially exhibits DNA replication stress and damages upon its oncogenesis. Thus, in this study, we examined the molecular characterization of BCL11B expression in hepatocellular carcinoma.Methods and ResultsThe cumulative progression‐free survival and overall survival were significantly longer in the clinical cases of BCL11B‐negative hepatocellular carcinoma than BCL11B‐positve cases. Microarray and real‐time PCR analyses in hepatocellular carcinoma cell lines indicated a correlation between BCL11B and GATA6, a gene reported to be correlated with oncogenic activities and resistance to anthracycline, which is often used for hepatocellular carcinoma chemotherapy. Consequently, BCL11B‐overexpressing cell lines exhibited resistance to anthracycline in cell growth assays and the resistance has been evidenced by the increased expression of BCL‐xL in cell lines. The results were supported by the analyses of human HCC samples showing the correlation between BCL11B and GATA6 expressions.Discussions and ConclusionOur results indicated that overexpression of BCL11B amplifies GATA6 expression in hepatocellular carcinoma in vitro and in vivo that leads to anti‐apoptotic signal activation, and induces resistance to chemotherapy, which influenced the postoperative prognosis.

show abstract